Related Experiment Video
Updated: Jul 19, 2026
14:14
Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications
Published on: February 28, 2014
Extrapulmonary small cell cancer: a Canadian province's experience
Kamal Haider1, Rabia K Shahid, Daygen Finch
1Department of Medical Oncology, Saskatoon Cancer Center, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Cancer
|September 26, 2006
Summary
Extrapulmonary small cell carcinoma (EPSCC) survival is influenced by primary tumor site, disease extent, and patient health. Gynecologic tumors offered the best prognosis, while abnormal white blood cell counts and poor performance status predicted mortality.
Area of Science:
- Oncology
- Medical Statistics
Background:
- Extrapulmonary small cell carcinoma (EPSCC) is a rare diagnosis.
- Identifying prognostic factors is crucial for patient management.
Purpose of the Study:
- To determine variables correlating with survival in patients diagnosed with EPSCC.
- To identify prognostic factors for mortality in EPSCC.
Main Methods:
- Retrospective review of 101 EPSCC patient records from Saskatchewan (1971-2002).
- Kaplan-Meier method for survival analysis.
- Logistic regression with backward elimination to identify predictors of mortality.
Main Results:
- Gastrointestinal (20%), genitourinary (18%), and unknown primary sites (31%) were most common.
- Median survival for limited disease (LD) was 34 months vs. 2 months for extensive disease (ED).
- Gynecologic SCC showed the best median survival (54.4 months); unknown primary had the worst (2.5 months).
- Abnormal white blood cell count (OR 6.9), Eastern Cooperative Oncology Group performance status >2 (OR 4.5), and ED (OR 2.7) significantly predicted mortality.
Conclusions:
- Gastrointestinal and genitourinary tracts are frequent origins of EPSCC.
- Prognosis varies significantly by primary tumor site, with gynecologic tumors having the best outcomes.
- Abnormal white blood cell count, poor performance status, and extensive disease are key predictors of survival in EPSCC.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...